Michal Reid, MD | |
200 1st St Sw, Rochester, MN 55905-0001 | |
(507) 284-2511 | |
Not Available |
Full Name | Michal Reid |
---|---|
Gender | Male |
Speciality | Critical Care (intensivists) |
Experience | 9 Years |
Location | 200 1st St Sw, Rochester, Minnesota |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003290610 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | 69153 (Minnesota) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Of Kansas Hospital | Kansas city, KS | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Kansas University Physicians, Inc. | 8921911587 | 1456 |
News Archive
Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.
Speedway Children's Charities and the National Rifle Association are partnering with the Starkey Hearing Foundation to deliver the gift of hearing to more than 70 underserved children and adults throughout the Carolinas on May 10, noon to 4pm, at Charlotte Motor Speedway.
The largest study of its type has found that neither vitamin E, which is an antioxidant, nor the diabetes drug metformin, successfully reduced liver enzymes in nonalcoholic fatty liver disease in children or teens, according to a paper published in the April 27, 2011 issue of Journal of the American Medical Association.
Genzyme announced today that it has filed a lawsuit in the District Court of Tel Aviv alleging that Transkaryotic Therapies Inc. has infringed Genzyme's Israeli patent No. 100,715, which covers certain cell culture processes involved in the manufacture of glucocerebrosidase.
A new study from Karolinska Institutet in Sweden shows that behavioural treatment for inducing weight-loss can be very effective for severely obese children. However, the treatment to change dietary and exercise habits must be given in time, as it showed to have little effect on adolescents with the same problem.
› Verified 9 days ago
Entity Name | Kansas University Physicians, Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.
Speedway Children's Charities and the National Rifle Association are partnering with the Starkey Hearing Foundation to deliver the gift of hearing to more than 70 underserved children and adults throughout the Carolinas on May 10, noon to 4pm, at Charlotte Motor Speedway.
The largest study of its type has found that neither vitamin E, which is an antioxidant, nor the diabetes drug metformin, successfully reduced liver enzymes in nonalcoholic fatty liver disease in children or teens, according to a paper published in the April 27, 2011 issue of Journal of the American Medical Association.
Genzyme announced today that it has filed a lawsuit in the District Court of Tel Aviv alleging that Transkaryotic Therapies Inc. has infringed Genzyme's Israeli patent No. 100,715, which covers certain cell culture processes involved in the manufacture of glucocerebrosidase.
A new study from Karolinska Institutet in Sweden shows that behavioural treatment for inducing weight-loss can be very effective for severely obese children. However, the treatment to change dietary and exercise habits must be given in time, as it showed to have little effect on adolescents with the same problem.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Michal Reid, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Michal Reid, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.
Speedway Children's Charities and the National Rifle Association are partnering with the Starkey Hearing Foundation to deliver the gift of hearing to more than 70 underserved children and adults throughout the Carolinas on May 10, noon to 4pm, at Charlotte Motor Speedway.
The largest study of its type has found that neither vitamin E, which is an antioxidant, nor the diabetes drug metformin, successfully reduced liver enzymes in nonalcoholic fatty liver disease in children or teens, according to a paper published in the April 27, 2011 issue of Journal of the American Medical Association.
Genzyme announced today that it has filed a lawsuit in the District Court of Tel Aviv alleging that Transkaryotic Therapies Inc. has infringed Genzyme's Israeli patent No. 100,715, which covers certain cell culture processes involved in the manufacture of glucocerebrosidase.
A new study from Karolinska Institutet in Sweden shows that behavioural treatment for inducing weight-loss can be very effective for severely obese children. However, the treatment to change dietary and exercise habits must be given in time, as it showed to have little effect on adolescents with the same problem.
› Verified 9 days ago
Emily Leasure, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jorge A Velosa, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michael Ruediger Mueller, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Mr. Karun Singh Badwal, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Katherine Desprez Wick, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Allison Bock, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |